The Ohio State University Wexner Medical Center, Columbus, OH, 43228, USA.
J Thromb Thrombolysis. 2021 May;51(4):1050-1058. doi: 10.1007/s11239-020-02286-2. Epub 2020 Oct 9.
The introduction of direct oral anticoagulants (DOACs) to the market has expanded anticoagulation options for outpatient use. Routine evaluation by health care professionals is recommended as it is with warfarin, therefore requiring adjustments in practices of anticoagulation management services (AMS). This study aims to describe trends that occurred following the incorporation of DOACs into AMS at a large academic medical center. A retrospective chart review of pharmacist-run AMS was used to compare patients on DOAC therapy versus other types of anticoagulation, including warfarin and parenteral agents. Primary outcomes included trends in the number of unique patients, management encounters, and telephone encounters throughout the study period. Secondary outcomes included trends in new encounters, and changes in patient characteristics, resources utilized, and patient satisfaction scores. A total of 2976 unique patients, 74,582 management encounters, and 13,282 telephone encounters were identified. From study beginning to end, results showed stable numbers of unique patients, an increase in management encounters for the DOAC group and decrease in the other anticoagulants group, and stable numbers of telephone encounters. Additionally, the number of new encounters for both groups increased. Throughout the study, pharmacy resources were reallocated within anticoagulation to adapt to the changing trends and patient satisfaction reached targets. Patients' characteristics remained stable, with the DOAC group having fewer comorbid conditions and concomitant medications that could increase bleed risk. This study showed that by reallocating resources within anticoagulation, AMS can maintain stable patient populations while continuing to expand access and satisfy patients following DOAC inclusion.
直接口服抗凝剂(DOACs)的引入扩大了门诊抗凝治疗的选择。建议医护人员进行常规评估,就像使用华法林一样,因此需要调整抗凝管理服务(AMS)的实践。本研究旨在描述在大型学术医疗中心将 DOAC 纳入 AMS 后发生的趋势。通过对药师管理的 AMS 进行回顾性图表审查,比较了 DOAC 治疗患者与其他类型抗凝治疗(包括华法林和肠外制剂)的患者。主要结果包括研究期间独特患者数量、管理就诊和电话就诊的趋势。次要结果包括新就诊的趋势以及患者特征、资源利用和患者满意度评分的变化。共确定了 2976 名独特患者、74582 次管理就诊和 13282 次电话就诊。从研究开始到结束,结果显示独特患者数量稳定,DOAC 组管理就诊次数增加,其他抗凝剂组减少,电话就诊次数稳定。此外,两组的新就诊次数均增加。在整个研究过程中,药剂科资源在抗凝治疗中重新分配,以适应不断变化的趋势,患者满意度达到目标。患者特征保持稳定,DOAC 组的合并症和同时使用的增加出血风险的药物较少。本研究表明,通过在抗凝治疗中重新分配资源,AMS 可以在继续扩大 DOAC 应用的同时,保持稳定的患者群体并满足患者的需求。